Lars Nieba

Engimmune Therapeutics is targeting malignant and inflamed tissue with soluble TCRs TCR-based therapies are an emerging class of drugs leveraging highly specific recognition of tumour and tissue antigens to enable precision immunotherapy. In oncology, soluble TCR approaches provide a unique mechanism of action that addresses many obstacles associated with targeting solid tumours, including: Targeting of intracellular antigens High-affinity binding to low-copy number peptide targets Tumour-targeted biodistribution Sustained recruitment of effector immune cells In immune-mediated disease, soluble TCRs enable high affinity targeting of tissue antigens to suppress the immune system at the site of disease, facilitating: Biodistribution targeted to inflamed tissues T cell inhibition at the site of inflammation Blockade of autoantigen recognition Long serum half-life for less frequent dosing